MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Add as a preferred source on Google
Daewoong Pharmaceuticals struck a deal with Zydus Worldwide DMCC to co-develop anti-cancer injectables in the United States. For this tie-up, the companies signed an agreement worth $92 million.
Korea’s Daewoong and UAE-based Zydus Group aim to market Leuprolide acetate through their licensing deal for the development of a generic of Lupron Depot drug, a leuprolide acetate for depot suspension, that is used for the treatment of advanced prostate cancer, uterine fibroids, and endometriosis. As per The Korea Herald, the former announced its exclusive licensing contract with the latter on Monday, Dec. 11.
Terms of the Deal: Division of Responsibilities
It was stipulated in the agreement that Daewoong would be in charge of preclinical research, studies, production, and supply of the generic called the DWJ108U. The Korean firm shared that it will manufacture the drug at its production plant in Osong, located in North Chungcheong Province.
On the other hand, Zydus will be responsible for all clinical trials and the commercialization of the DWJ108U in the U.S. “Together with Zydus, Daewoong Pharmaceutical will aim to develop and commercialize a generic of AbbVie’s Lupron Depot in the U.S. market,” an official of the Korean pharma company said in a statement.
Contract Period and Payment Agreement
Korea BioMedical Review reported that Daewoong and Zydus agreed to work together for seven years following the first sale. The total value of the licensing deal is about $92.4 million, which will be paid in various forms, including $25.5 million in a commercialization milestone payment and the remaining $66.9 million to be settled soon after the drug’s possible launch in the U.S. market.
Jeon Seng Ho, Daewoong Pharmaceutical’s chief executive officer, said, “Given the complexity, complex generic drug products like Lupron Depot do not exist to date, and we aim to be the first company to manufacture the generic version of this complex, long-acting injectable Lupron Depot product.”
Lastly, Zydus Lifesciences’ managing director, Sharvil Patel, added, “This is an important milestone and we are happy to work with Daewoong for the generic version of Lupron Depot.”
Photo by: Zydus Life Media Kit
